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Combined inhibition of Chk1 and Wee1 kinases for cancer treatment S. Hauge Purpose or Objective: Inhibition of checkpoint kinases Wee1 or Chk1 causes G2-checkpoint abrogation and mitotic catastrophe, particularly in p53 defective tumors. Based on this, Wee1 and Chk1 inhibitors are currently in clinical trials, combined with radiation or chemo-therapy. However, our previous work has shown that inhibition of Wee1 or Chk1 also causes DNA breakage in S-phase, largely due to high Cyclin-Dependent-Kinase (CDK)-activity followed by unscheduled replication initiation. Furthermore, recent work by others has shown synergistic anti-cancer effects after combined Wee1 and Chk1 inhibition. The aim of this study was to investigate whether S-phase DNA damage may contribute to the synergistic effects after combined Chk1/Wee1 inhibition.
Material and Methods:
Osteosarcoma U2OS and lung cancer A549, H460 and H1975 cells were exposed to the Wee1 inhibitor MK1775 and/or the Chk1 inhibitors AZD7762, LY2606368, MK8776 and UCN01. The DNA damage marker gH2AX was analyzed in S-phase cells by flow cytometry. DNA damage signaling and inhibitory phosphorylation of CDK1 and CDK2 were examined by immunoblotting, and cell survival by clonogenic survival assays. CDK activity was measured in Sphase cells by a novel flow cytometry barcoding method. In this method, CDK-dependent phosphorylations (antibodies to phospho-BRCA2 S3291, phospho-bMyb T487 and phospho-Mpm2) versus DNA content (Hoechst staining) were examined in individual cells. Barcoding with Pacific Blue was included to reduce sample-to-sample variations. Loading of the replication initiation factor CDC45 was measured by a similar flow cytometry method and by immunoblotting after removal of unbound proteins by extraction with salt and detergent.
Results:
We observed a strong synergy in induction of S-phase damage after combined Wee1 and Chk1 inhibition. Also, clonogenic survival was strongly decreased after the combined treatment. Surprisingly, this synergy could not be explained by increased CDK-activity, as S-phase CDK-activity did not correlate with induction of DNA damage after Wee1 and Chk1 inhibition. Wee1 inhibition caused a bigger increase in CDK-activity than Chk1 inhibition. However, Chk1 inhibition caused more S-phase damage and loading of the replication factor CDC45. The combination of Wee1 and Chk1 inhibitors further increased the CDC45 loading, and the extent of CDC45 loading correlated with DNA damage induction.
Conclusion:
We have shown for the first time that combined Wee1 and Chk1 inhibition causes synergistic S-phase DNA damage, due to distinct effects of Wee1 and Chk1 kinases in regulation of CDK activity and CDC45 loading, respectively. This synergy can explain the synergistic anti-cancer effects obtained by simultaneous Chk1/Wee1 inhibition. We propose that combined Chk1/Wee1 inhibition may be useful together with radiation therapy to eliminate radioresistant S-phase cells.
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Anti-GRP 78 antibodies bind specifically to cancers enhance efficacy of radiotherapy in cancer D. Dadey Purpose or Objective: Purpose: Glioblastoma demonstrates progression of disease within the high dose region of radiotherapy, in nearly all cases. The physiologic response within glioblastoma to radiation is in part dependent upon a pro-survival signaling. GRP78 was first described to regulate cellular stresses, including hypoglycemia, hypoxia and the ER stress response. GRP78 is an important regulator of cell stress, and binds to several pro-survival proteins. Antagonists to GRP78 include Kringle-5 and PAR4 which induce apoptosis in tumor vasculature endothelium and cancer cells. The molecular events that result from the ER stress response can enhance cell viability. GRP78 is overexpressed in poor prognosis cancers and is a molecular therapeutic target in poorly differentiated cancers.
Material and Methods:
Methods: We studied radiation induction of GRP78 by western immunoblot and flow cytometry. We used siRNA to knock down GRP78 in human GBM and NSCLC cell lines. In order to study the potential relationship between radiation dose and induction of ATF6 activity, we treated D54 cells with 3 Gy and 6 Gy and analyzed GRP78 protein expression 48h after irradiation. We utilized Anti-GRP78 antibodies administered IV to mouse models of human cancer xenografts. We measured tumor growth delay using subcutaneous implants of human cancer xenografts.
Results:
Results: We found that radiation induces the expression of GRP78 in glioblastoma. Antibodies to GRP78 enhanced radiation-induced cytotoxicity in glioblastoma but not normal cells. We found that radiation induced GRP78 expression is regulated through the ER stress response, and that ATF6 is responsible for the transcriptional induction of GRP78. Knockdown of ATF6 abrogates GRP78 induction and enhanced cytotoxicity from radiation. Moreover interruption of GRP78 signaling enhances therapeutic effects of radiation. GRP78 antibodies enhanced cytotoxicity from radiation in human glioblastoma and NSCLC cell lines. We found that the levels of GRP78 protein were elevated at the 48 and 72h time points. Knockdown of ATF6 was sufficient to abrogate GRP78 induction. We observed dose dependent increases in GRP78 levels, which were reproducible when the experiment was repeated with LN827 cells. Similar changes were observed in GRP78 mRNA levels 48h after IR, where a 75% and 100% increase was observed in D54. Anti-GRP-78 antibodies bind specifically to irradiated cancers enhanced the efficacy of radiotherapy in human cancer models in vitro and in mouse xenografts.
Conclusion:
Conclusion: GRP78 is a molecular target for the development of novel radiation sensitizing agents. Anti-GRP78 antibodies enhance the efficacy of radiotherapy when administered IV to mouse models of human cancer. Material and Methods: Surgical tumor tissue samples were obtained from 40 patients. MiR-143 and STAT3 protein expression levels in these clinical samples and three ESCC cell lines were determined by quantitative RT-PCR and western blot. The relationship between expression level of miR-143 and clinical parameters were explored by one-way ANOVA. The specific targeting site of miR-143 in the 3'-UTR of STAT3 was identified using dual-luciferase reporter assays. Then, the effects of ectopic miR-143 or STAT3 expression on proliferation, cell cycle distribution, migration and invasion were determined in colony-forming assay, flow cytometry and transwell assay. The effect of miR-432 on tumor progression in vivo was determineded by performing tumor formation assay in nude mice. The role miR-143 in regulating cell cycle signaling, epithelial-mesenchymal transition and MMP up-regulation through repressing STAT3 was explored by analyzing the expression level of the downstream proteins.
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Results: MiR-143 expression was downregulated in 90% of the ESCC clinical samples and its expression level was associated with the lymph node metastasis(LNM), invasion and TNM stage in ESCC patients. Functional experiments showed that ectopic expression of miR-143 could inhibit tumor cell proliferation, migration and invasion by supressing STAT3 in vitro. Animal experiments showed that the size of subcutaneous tumors derived from miR-143 overexpressing cells were significantly smaller than that of empty vector expressing cells. Further studies verified that miR-143 might regulate cell cycle, EMT and MMP up-regulation by targeting STAT3 and hence, lead to the suppresion of ESCC cell proliferation, migration and invasion.
Conclusion:
Our study showed that miR-143 could act as a tumor suppressor through the inhibition of proliferation, migration and invasion by directly targeting STAT3 and subsequently mediates the downstream proteins. Thus, miR-143 has significant value in clinical and may serve as a prognostic marker and therapeutic target in the future. 
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